AMENDMENTS TO THE CLAIMS

1. (currently amended) A compound having the structure

$$I\text{-}X\text{-}(C{=}Y)_m\text{-}L\text{-}A$$

wherein I is an HIV protease inhibitor ~~radical~~ selected from the group consisting of ritonavir, saquinavir, amprenavir, indinavir, nelfinavir, lopinavir, and atazanavir, said inhibitor lacking only a hydroxyl or an amino group,

X is O or ~~NH~~ NR wherein R is H or lower alkyl,

Y is O, S or NH,

m is 0 or 1,

L is a linker ~~consisting of~~ comprising from 0 to 40 carbon atoms arranged in a straight chain or a branched chain, saturated or unsaturated, and containing up to two ring structures and 0-20 heteroatoms, with the proviso that not more than two heteroatoms may be linked in sequence, and

A is an activated functionality chosen from the group consisting of active esters, isocyanates, isothiocyanates, thiols, imidoesters, anhydrides, maleimides, thiolactones, diazonium groups and aldehydes.

2. (cancelled)

3. (original) The compound of claim 1 wherein X is O, Y is O and m is 1.

4. (original) The compound of claim 1 wherein X is NH, Y is O and m is 1.

5. (original) The compound of claim 1 wherein X is O, Y is O, m is 1 and the first atom in L adjacent to C=Y is N.

6. (original) The compound of claim 1 wherein X is NH, Y is O, m is 1 and the first atom in L adjacent to C=Y is N.

7. (original) The compound of claim 1 wherein X is NH, Y is S, m is 1 and the first atom in L adjacent to C=Y is N.

8. (original) The compound of claim 1 wherein X is NH, Y is NH and m is 1.

9. (original) The compound of claim 1 wherein X is O and m is 0.

10. (cancelled)

11. (original) The compound O^c-(succinimido-oxycarbonyl-butyryl-aminocaproyl)-ritonavir (**1C**).

12. (original) The compound O^c-[4'-(succinimido-oxycarbonyl)-benzoyl-aminocaproyl]-ritonavir (**1D**).

13. (original) The compound O^c-(succinimido-oxycarbonyl-butyryl-aminocaproyl)-saquinavir (**2C**).

14. (original) The compound O^c-[4'-(succinimido-oxycarbonyl)-benzoyl-aminocaproyl]-saquinavir (**2F**).

15. (original) The compound O^c-(succinimido-oxycarbonyl-butyryl-aminocaproyl)-amprenavir (**3C**).

16. (original) The compound O^c-[4'-(succinimido-oxycarbonyl)-benzoyl-aminocaproyl]-amprenavir (**3D**).

17. (original) The compound O^c-(succinimido-oxycarbonyl-butyryl-aminocaproyl)-indinavir (**4E**).

18. (original) The compound O^c-[4'-(succinimido-oxycarbonyl)-benzoyl-aminocaproyl]-indinavir (**4F**).

19. (original) The compound O^c-(succinimido-oxycarbonyl-butyryl-aminocaproyl)-nelfinavir (**5D**).

20. (original) The compound O^c-[4'-(succinimido-oxycarbonyl)-benzoyl-aminocaproyl]-nelfinavir (**5E**).

21. (original) The compound O^c-(succinimido-oxycarbonyl-butyryl-aminocaproyl)-lopinavir (**6C**).

22. (original) The compound O^c-[4'-(succinimido-oxycarbonyl)-benzoyl-aminocaproyl]-lopinavir (**6D**).

23. (original) The compound O^c-(succinimido-oxycarbonyl-butyryl-aminocaproyl)-atazanavir (**7C**).

24. (original) The compound O^c-[4'-(succinimido-oxycarbonyl)-benzoyl-aminocaproyl]- atazanavir (**7D**).

25. (original) The compound O^c-[4'-(succinimido-oxycarbonyl)-phenyl-aminocarbonyl]-saquinavir (**2U**).

26. (original) The compound O^c-(succinimido-oxycarbonyl-methylaminocarbonyl)-saquinavir (**2L**).

27. (original) The compound O^c-[4'-(succinimido-oxycarbonyl)-phenyl-methylamino-^{co}-glycyl-carbonyl]-saquinavir (**2Y**).

28. (original) The compound O^c-(succinimido-oxycarbonyl-propylamino-^{co}-glycyl-glycyl-glycyl-carbonyl)-nelfinavir (**5S**).

29. (original) The compound O^c-(succinimido-oxycarbonyl-methyl)-saquinavir (**2BB**).

30. (original) The compound O^{ar}-MEM-O^c-(succinimido-oxycarbonyl-methyl)-nelfinavir (**5O**).

31. (currently amended) A compound having the structure

$$[I\text{-}X\text{-}(C{=}Y)_m\text{-}L\text{-}Z]_n\text{-}P$$

wherein I is an HIV protease inhibitor ~~radical~~ selected from the group consisting of ritonavir, saquinavir, amprenavir, indinavir, nelfinavir, lopinavir, and atazanavir, said inhibitor lacking only a hydroxyl or an amino group,

X is O or ~~NH~~ NR wherein R is H or lower alkyl,

Y is O, S, or NH,

m is 0 or 1,

L is a linker comprising 0 to 40 carbon atoms arranged in a straight chain or a branched chain, saturated or unsaturated, and further comprising up to two ring structures and 0-20 heteroatoms, with the proviso that not more than two heteroatoms are linked in sequence,

Z is a moiety selected from the group consisting of -CONH-, -NHCO-, -NHCONH-, -NHCSNH-, -OCONH-, -NHOCO-, -S-, -NH(C=NH)-, -N=N-, -NH-, and  ,

P is selected from the group consisting of polypeptides, polysaccharides and synthetic polymers, and

n is a number from 1 to 50 per 50 kilodaltons molecular weight of P.

32. (cancelled)

33. (original) The compound of claim 31 wherein P is an aminated dextran.

34. (original) The compound of claim 31 wherein P is bovine serum albumin.

35. (original) The compound of claim 31 wherein P is keyhole limpet hemocyanin.

36. (original) The compound of claim 31 wherein P is *Limulus polyphemus* hemocyanin.

37. (original) The compound of claim 31 wherein P is bovine thyroglobulin.

38. (original) The compound O^c-(succinimido-oxycarbonyl-butyryl-aminocaproyl)-ritonavir conjugate with LPH (**1E**).

39. (original) The compound O^c-[4'-(succinimido-oxycarbonyl)-benzoyl-aminocaproyl]-ritonavir conjugate with BSA (**1F**).

40. (original) The compound O^c-(succinimido-oxycarbonyl-butyryl-aminocaproyl)-saquinavir conjugate with KLH (**2E**).

41. (original) The compound O^c-[4'-(succinimido-oxycarbonyl)-benzoyl-aminocaproyl]-saquinavir conjugate with BSA (**2G**).

42. (original) The compound O^c-(succinimido-oxycarbonyl-butyryl-aminocaproyl)-amprenavir conjugate with KLH (**3E**).

43. (original) The compound O^c-[4'-(succinimido-oxycarbonyl)-benzoyl-aminocaproyl]-amprenavir conjugate with BSA (**3F**).

44. (original) The compound O^c-[(succinimido-oxycarbonyl)-butyryl-aminocaproyl]-indinavir conjugate with KLH (**4G**).

45. (original) The compound O^c-[4'-(succinimido-oxycarbonyl)-benzoyl-aminocaproyl]-indinavir conjugate with BSA (**4H**).

46. (original) The compound O^c-(succinimido-oxycarbonyl-butyryl-aminocaproyl)-nelfinavir conjugate with KLH (**5F**).

47. (original) The compound O^c-[4'-(succinimido-oxycarbonyl)-benzoyl-aminocaproyl]-nelfinavir conjugate with BSA (**5G**).

48. (original) The compound O^c-(succinimido-oxycarbonyl-butyryl-aminocaproyl)-lopinavir conjugate with KLH (**6F**).

49. (original) The compound O^c-[4'-(succinimido-oxycarbonyl)-benzoyl-aminocaproyl]-lopinavir conjugate with BSA (**6E**).

50. (original) The compound O^c-[4'-(succinimido-oxycarbonyl)-benzoyl-aminocaproyl]-atazanavir conjugate with BSA (**7F**).

51. (original) The compound O^c-(succinimido-oxycarbonyl-butyryl-aminocaproyl)-atazanavir conjugate with KLH (**7E**).

52. (currently amended) A compound having the structure

$$[I\text{-}X\text{-}(C{=}Y)_m\text{-}L\text{-}Z]_n\text{-}Q$$

wherein I is an HIV protease inhibitor ~~radical~~ selected from the group consisting of ritonavir, saquinavir, amprenavir, indinavir, nelfinavir, lopinavir, and atazanavir, said inhibitor lacking only a hydroxyl or an amino group,

X is O or ~~NH~~ NR wherein R is H or lower alkyl,

Y is O, S, or NH,

m is 0 or 1,

L is a linker comprising 0 to 40 carbon atoms arranged in a straight chain or a branched chain, saturated or unsaturated, and further comprising up to two ring structures and 0-20 heteroatoms, with the proviso that not more than two heteroatoms are linked in sequence,

Z is a moiety chosen from the group consisting of -CONH-, -NHCO-,-NHCONH-, -NHCSNH-, -OCONH-, -NHOCO-, -S-, -NH(C=NH)-, -N=N-, -NH-, and  ,

Q is selected from the group consisting of non-isotopic labels,

and n is a number from 1 to 50 per 50 kilodaltons molecular weight of Q.

53. (cancelled)

54. (original) The compound of claim 52 wherein Q is biotin.

55. (original) The compound O^c-[4'-(1-biotinyl-amino-3,6-dioxa-octylamino)-terephthaloyl-aminocaproyl]-amprenavir (**3J**).

56. (original) The compound O^c-[4'-(1-biotinyl-amino-3,6-dioxa-octylamino)-terephthaloyl-aminocaproyl]-lopinavir (**6G**).

57. (original) The compound O^c-[4'-(1-biotinyl-amino-3,6-dioxa-octylamino)-terephthaloyl-aminocaproyl]-ritonavir (**1J**).

58. (original) The compound O^c-[4'-(1-biotinyl-amino-3,6-dioxa-octylamino)-terephthaloyl-aminocaproyl]-indinavir (**4I**).

59. (currently amended) An antibody generated in response to a compound having the structure:

$$[I\text{-}X\text{-}(C{=}Y)_m\text{-}L\text{-}Z]_n\text{-}P$$

wherein I is an HIV protease inhibitor ~~radical~~ selected from the group consisting of ritonavir, saquinavir, amprenavir, indinavir, nelfinavir, lopinavir, and atazanavir, said inhibitor lacking only a hydroxyl or an amino group,

X is O or ~~NH~~ NR wherein R is H or lower alkyl,

Y is O, S, or NH,

m is 0 or 1,

L is a linker comprising 0 to 40 carbon atoms arranged in a straight chain or a branched chain, saturated or unsaturated, and further comprising up to two ring structures and 0-20 heteroatoms, with the proviso that not more than two heteroatoms are linked in sequence,

Z is a moiety selected from the group consisting of -CONH-, -NHCO-, -NHCONH-, -NHCSNH-, -OCONH-, -NHOCO-, -S-, -NH(C=NH)-, -N=N-, -NH-, and  ,

P is selected from the group consisting of polypeptides, a polysaccharides, and synthetic polymers,

and n is a number from 1 to 50 per 50 kilodaltons molecular weight of P.

60. (cancelled)

61. (original) An antibody generated in response to the compound of claim 38.

62. (original) An antibody generated in response to the compound of claim 40.

63. (original) An antibody generated in response to the compound of claim 42.

64. (original) An antibody generated in response to the compound of claim 44.

65. (original) An antibody generated in response to the compound of claim 46.

66. (original) An antibody generated in response to the compound of claim 48.

67. (original) A monoclonal antibody specific for saquinavir having less than 10% cross-reactivity with nelfinavir, indinavir, amprenavir, ritonavir and lopinavir.

68. (original) A monoclonal antibody specific for nelfinavir having less than 10% cross-reactivity with saquinavir, indinavir, amprenavir, ritonavir and lopinavir.

69. (original) A monoclonal antibody specific for indinavir having less than 10% cross-reactivity with saquinavir, nelfinavir, amprenavir, ritonavir and lopinavir.

70. (original) A monoclonal antibody specific for amprenavir having less than 10% cross-reactivity with saquinavir, nelfinavir, indinavir, ritonavir and lopinavir.

71. (original) A monoclonal antibody specific for lopinavir having less than 10% cross-reactivity with saquinavir, nelfinavir, amprenavir, ritonavir and indinavir.

72. (original) A monoclonal antibody specific for ritonavir having less than 10% cross-reactivity with saquinavir, nelfinavir, amprenavir, indinavir and lopinavir.

73. (original) Murine hybridoma SAQ 10.2.1 having ATCC No. PTA-3973.

74. (original) Murine hybridoma SAQ 14.1.1 having ATCC No. PTA-3974.

75. (original) Murine hybridoma NEL 5.4.1 having ATCC No. PTA-4475.

76. (original) Murine hybridoma <INDIN> M 1.003.12 having DSMZ No. ACC2547.

77. (original) Murine hybridoma <INDIN> M 1.158.8 having DSMZ No. ACC2546.

78. (original) Murine hybridoma <AMPREN> M 1.1.52 having DSMZ No. ACC 2612.

79. (original) Murine hybridoma <LOPIN> M 1.1.85 having DSMZ No. ACC 2611.

80. (original) Murine hybridoma <RITON> M 1.5.44 having DSMZ No. ACC 2613.